Cuprina Holdings (Cayman) (CUPR) Competitors

$0.27 0.00 (0.00%)

Closing price 05/22/2026 03:50 PM Eastern

Extended Trading

$0.26 -0.01 (-2.56%)

As of 05/22/2026 07:55 PM Eastern

CUPR vs. SNSE, AYTU, AEON, HOWL, and ANEB

Should you buy Cuprina Holdings (Cayman) stock or one of its competitors? MarketBeat compares Cuprina Holdings (Cayman) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cuprina Holdings (Cayman) include Sensei Biotherapeutics (SNSE), Aytu BioPharma (AYTU), AEON Biopharma (AEON), Werewolf Therapeutics (HOWL), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry.

How does Cuprina Holdings (Cayman) compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Sensei Biotherapeutics currently has a consensus price target of $45.00, suggesting a potential upside of 152.95%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cuprina Holdings (Cayman) has higher revenue and earnings than Sensei Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Cuprina Holdings (Cayman)	$40K	141.70	-$3.63M	N/A	N/A

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 2 articles in the media. Sensei Biotherapeutics' average media sentiment score of 0.00 beat Cuprina Holdings (Cayman)'s score of -0.19 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-803.00%	-256.50%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Summary

Sensei Biotherapeutics beats Cuprina Holdings (Cayman) on 6 of the 10 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Aytu BioPharma?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.22 beat Cuprina Holdings (Cayman)'s score of -0.19 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$40K	141.70	-$3.63M	N/A	N/A
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

Aytu BioPharma has a consensus price target of $9.33, indicating a potential upside of 326.18%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Aytu BioPharma beats Cuprina Holdings (Cayman) on 7 of the 13 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Cuprina Holdings (Cayman) has higher revenue and earnings than AEON Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Cuprina Holdings (Cayman)	$40K	141.70	-$3.63M	N/A	N/A

In the previous week, Cuprina Holdings (Cayman) had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 0 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 beat Cuprina Holdings (Cayman)'s score of -0.19 indicating that AEON Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
AEON Biopharma	Neutral
Cuprina Holdings (Cayman)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

22.8% of AEON Biopharma shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AEON Biopharma beats Cuprina Holdings (Cayman) on 6 of the 10 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Werewolf Therapeutics had 2 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 4 mentions for Werewolf Therapeutics and 2 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of -0.19 beat Werewolf Therapeutics' score of -0.29 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cuprina Holdings (Cayman) has lower revenue, but higher earnings than Werewolf Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A
Cuprina Holdings (Cayman)	$40K	141.70	-$3.63M	N/A	N/A

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Werewolf Therapeutics currently has a consensus price target of $3.75, suggesting a potential upside of 745.36%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Werewolf Therapeutics beats Cuprina Holdings (Cayman) on 7 of the 12 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Cuprina Holdings (Cayman) has higher revenue and earnings than Anebulo Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Cuprina Holdings (Cayman)	$40K	141.70	-$3.63M	N/A	N/A

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 beat Cuprina Holdings (Cayman)'s score of -0.19 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anebulo Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cuprina Holdings (Cayman) beats Anebulo Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Cuprina Holdings (Cayman) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUPR vs. The Competition

Export

Metric	Cuprina Holdings (Cayman)	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$5.67M	$927.43M	$4.26B	$12.34B
Dividend Yield	N/A	4.84%	5.93%	5.28%
P/E Ratio	N/A	1.46	21.90	25.66
Price / Sales	141.70	119.63	180.59	86.31
Price / Cash	N/A	20.07	55.68	56.67
Price / Book	1.42	7.59	34.85	7.14
Net Income	-$3.63M	-$3.64M	$112.32M	$335.98M
7 Day Performance	0.56%	3.01%	3.54%	4.11%
1 Month Performance	-9.91%	76.62%	3.58%	2.52%
1 Year Performance	N/A	126.61%	15.80%	35.04%

Cuprina Holdings (Cayman) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUPR Cuprina Holdings (Cayman)	1.2163 of 5 stars	$0.27 flat	N/A	N/A	$5.67M	$40K	N/A	14	Gap Down
SNSE Sensei Biotherapeutics	2.1957 of 5 stars	$17.58 +4.8%	$40.00 +127.5%	+201.0%	$22.50M	N/A	N/A	40	Gap Up
AYTU Aytu BioPharma	2.3346 of 5 stars	$2.15 +3.4%	$9.33 +334.1%	+11.7%	$22.33M	$66.38M	N/A	160
AEON AEON Biopharma	0.9912 of 5 stars	$0.86 +0.9%	N/A	+45.5%	$21.64M	N/A	4.79	5	Gap Up
HOWL Werewolf Therapeutics	3.05 of 5 stars	$0.44 +2.2%	$3.75 +756.2%	-61.4%	$20.82M	N/A	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUPR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cuprina Holdings (Cayman) (CUPR) Competitors

CUPR vs. SNSE, AYTU, AEON, HOWL, and ANEB

How does Cuprina Holdings (Cayman) compare to Sensei Biotherapeutics?

Summary

How does Cuprina Holdings (Cayman) compare to Aytu BioPharma?

Summary

How does Cuprina Holdings (Cayman) compare to AEON Biopharma?

Summary

How does Cuprina Holdings (Cayman) compare to Werewolf Therapeutics?

Summary

How does Cuprina Holdings (Cayman) compare to Anebulo Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUPR vs. The Competition

Cuprina Holdings (Cayman) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cuprina Holdings (Cayman) (CUPR) Competitors

CUPR vs. SNSE, AYTU, AEON, HOWL, and ANEB

How does Cuprina Holdings (Cayman) compare to Sensei Biotherapeutics?

Do analysts recommend SNSE or CUPR?

Do institutionals and insiders have more ownership in SNSE or CUPR?

Which has preferable earnings and valuation, SNSE or CUPR?

Does the media favor SNSE or CUPR?

Is SNSE or CUPR more profitable?

Summary

How does Cuprina Holdings (Cayman) compare to Aytu BioPharma?

Does the media prefer CUPR or AYTU?

Is CUPR or AYTU more profitable?

Which has better valuation and earnings, CUPR or AYTU?

Do analysts rate CUPR or AYTU?

Do insiders and institutionals hold more shares of CUPR or AYTU?

Summary

How does Cuprina Holdings (Cayman) compare to AEON Biopharma?

Which has better earnings and valuation, AEON or CUPR?

Does the media prefer AEON or CUPR?

Is AEON or CUPR more profitable?

Do institutionals and insiders believe in AEON or CUPR?

Do analysts rate AEON or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to Werewolf Therapeutics?

Does the media favor HOWL or CUPR?

Do insiders and institutionals hold more shares of HOWL or CUPR?

Which has better valuation & earnings, HOWL or CUPR?

Is HOWL or CUPR more profitable?

Do analysts rate HOWL or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to Anebulo Pharmaceuticals?

Which has preferable valuation & earnings, ANEB or CUPR?

Does the media prefer ANEB or CUPR?

Is ANEB or CUPR more profitable?

Do analysts prefer ANEB or CUPR?

Do institutionals and insiders hold more shares of ANEB or CUPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUPR vs. The Competition

Cuprina Holdings (Cayman) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools